Biotech
News Category
VERAXA Biotech Shareholders Overwhelmingly Approve Corporate Governance and Financing Measures
VERAXA Biotech AG shareholders approved all proposals at an Extraordinary General Meeting, including conditional share capital, a capital band through...
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the c...
Gerresheimer Doubles Production Capacity for Injectable Pharma Packaging in China with New Plant in Zhenjiang Dagang
Gerresheimer has started operations at a new, sustainable plant in Zhenjiang Dagang, China, doubling its production capacity for glass primary pharmac...
Helus Pharma Completes Enrollment in Phase 3 Depression Study for HLP003
Helus Pharma has completed enrollment in its pivotal Phase 3 APPROACH trial for HLP003, an investigational psilocin analogue for major depressive diso...
Darwin AG Rebrands as Novogenia AG to Unify Corporate and Brand Identity
Darwin AG has officially changed its name to Novogenia AG, aligning its corporate identity with its core operating brand to enhance market presence an...
NanoViricides Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC
NanoViricides progresses its broad-spectrum antiviral NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, offering a pot...
Redwood AI Corp. Added to CSE25 Index Following Quarterly Rebalancing
Redwood AI Corp. has been included in the CSE25 Index, reflecting its position among the largest companies on the Canadian Securities Exchange and pot...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Depression Trial on Track for Q4 Data
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with top-line data ex...
Quantum BioPharma's Lucid-MS Offers New Hope for Multiple Sclerosis Treatment
Quantum BioPharma Ltd. is advancing Lucid-MS, a first-in-class drug candidate designed to repair myelin damage in multiple sclerosis, into Phase 2 tri...
Drug Delivery Platforms Emerge as Key Frontier in Oncology Innovation, Attracting $410 Billion Market Interest
Oncotelic Therapeutics' nanoparticle-based Deciparticle platform highlights how advanced drug delivery could unlock value from existing oncology drugs...
Quantum BioPharma Advances Novel Multiple Sclerosis Therapy Lucid-MS Toward Phase 2 Trials
Quantum BioPharma Ltd. is progressing its patented drug candidate Lucid-MS, a non-immunomodulatory therapy that directly protects the myelin sheath, i...
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform
VERAXA Biotech announced new in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating tumor-restricted activation and potent killing o...
Redwood AI Corp. Positions Itself as a Key Player in AI-Powered Chemistry R&D
Redwood AI Corp. leverages proprietary AI platforms to accelerate chemistry research and development across pharmaceuticals, defense, and industrial s...
Helix BioPharma Reports Reduced Net Loss, Strengthens Cash Position with Private Placement
Helix BioPharma Corp. announced financial results showing a reduced net loss and increased cash reserves, driven by a private placement that extends o...
CNS Pharmaceuticals Details Oversubscribed $22.5 Million Financing and Growth Strategy
CNS Pharmaceuticals highlighted its oversubscribed $22.5 million financing and outlined its growth strategy during a virtual investor presentation, em...
Oncotelic Therapeutics Expands Sapu003 Phase 1b Program, Appoints Global CRO for International Study
Oncotelic Therapeutics and Sapu Nano have expanded their Phase 1b clinical program for Sapu003, a novel intravenous formulation of everolimus, and app...
Platform Biotech Models Gain Traction as Drug-Delivery Markets Approach $410 Billion
Rising oncology drug costs and regulatory challenges are driving biotech companies toward platform-based drug-delivery technologies, with the market p...
Quantum BioPharma Highlights Lucid-MS and unbuzzd™ Growth Opportunities on BioMedWire Podcast
Quantum BioPharma's co-founder discusses the potential of Lucid-MS for multiple sclerosis and the commercial progress of unbuzzd™, with an upcoming Ph...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth on BioMedWire Podcast
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by repairing nerve damage, while its commercial product u...
Quantum BioPharma Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities in BioMedWire Podcast
Quantum BioPharma Ltd. discusses its lead drug candidate Lucid-MS for multiple sclerosis and its commercial alcohol metabolism product unbuzzd(TM) on ...
Tonix Pharmaceuticals Reveals High Opioid Prescription Rates in Fibromyalgia Patients Despite Guidelines
Tonix Pharmaceuticals presented real-world data showing about 40% of fibromyalgia patients are prescribed opioids, highlighting a gap between practice...
Optimi Health Welcomes Australia’s Updated TGA Framework for Psychedelic Therapy Expansion
Optimi Health Corp. praised Australia’s revised Therapeutic Goods Administration rules that broaden psilocybin and MDMA prescribing, potentially accel...
Tonix Pharmaceuticals Reveals High Fibromyalgia Burden in Real-World Data at ISPOR 2026
Tonix Pharmaceuticals presented real-world claims analysis at ISPOR 2026 showing that over 93% of fibromyalgia patients have comorbidities and incur s...
Annovis Bio Regains NYSE Listing Compliance Following Corrective Measures
Annovis Bio Inc. has restored its NYSE listing compliance by addressing market capitalization and stockholders' equity requirements, ensuring its comm...
Oncotelic Therapeutics Integrates 28 Million Scientific Abstracts into AI Platform for Drug Discovery
Oncotelic Therapeutics (OTCQB: OTLC) has integrated approximately 28 million scientific abstracts into its proprietary PDAOAI platform, positioning it...
Sunshine Biopharma Closes $6 Million Public Offering to Fund Operations and Drug Development
Sunshine Biopharma Inc. has closed a $6 million public offering, with proceeds earmarked for general corporate purposes and working capital, and poten...
Cardio Diagnostics CEO Discusses Growth Strategy, India Expansion, and Medicare Progress on BioMedWire Podcast
Cardio Diagnostics Holdings CEO Dr. Meesha Dogan outlined the company's precision medicine approach to cardiovascular disease and announced expansion ...
Oragenics Advances Phase IIa Concussion Trial, Eyes CNS Device Licensing
Oragenics provided a shareholder update on its Phase IIa trial of ONP-002 for concussion in Australia, plans for U.S. regulatory steps, and a letter o...
Kairos Pharma to Showcase Clinical Progress at LD Micro Invitational XVI
Kairos Pharma CEO Dr. John Yu will present updates on the company's oncology pipeline, including Phase 2 trial for ENV-105 in prostate cancer, at the ...
Lantern Pharma to Report First Quarter 2026 Financial Results on May 15
Lantern Pharma announced it will release its first-quarter 2026 financial results on May 15, providing updates on clinical trials and AI platform deve...
MindBio Therapeutics Files Patent Applications for AI-Driven Voice Intoxication Detection Technology
MindBio Therapeutics has filed patent applications for 15 novel discoveries in AI-driven voice intoxication detection, targeting high-volume regulated...
Annovis Bio CEO to Present Alzheimer’s Multi-Protein Research at Fierce Biotech Week 2026
Annovis Bio CEO will present the company’s multi-protein targeting approach for Alzheimer’s at Fierce Biotech Week 2026, highlighting buntanetap’s pot...
Cardio Diagnostics Harnesses AI and Biomarkers to Advance Heart Disease Detection
Cardio Diagnostics Holdings Inc. is leveraging artificial intelligence and multi-omic biomarkers to improve early detection of cardiovascular disease,...
BioStem Technologies to Discuss Q1 2026 Financial Results in May 14 Conference Call
BioStem Technologies will release first quarter 2026 financial results on May 14 and host a conference call and webcast at 4:30 PM ET, providing an ov...
Earth Science Tech Inc. Leverages Vertical Integration to Target Precision Medicine Market
Earth Science Tech Inc. uses its vertically integrated model combining telemedicine, compounding pharmacy, and clinical services to address the growin...
BioAdaptives Launches MyndMed Cognitive-Support Supplement After Successful Testing and Strong Early Demand
BioAdaptives, Inc. has commercially launched MyndMed, a dietary supplement aimed at enhancing memory, focus, and brain performance, following positive...
Telomir Pharmaceuticals Acquires TELI, Secures Global Rights to Telomir-1
Telomir Pharmaceuticals closes acquisition of TELI Pharmaceuticals, obtaining sole global rights to Telomir-1 and consolidating its development for ca...